Telix Pharmaceuticals Limited has completed enrollment in the 350-patient Phase 3 BiPASS study, a pivotal trial testing whether PSMA-PET imaging can improve prostate-cancer detection before men undergo biopsy. The prospective trial is evaluating Telix’s gallium-68 PSMA imaging agents Illuccix and Gozellix in combination with magnetic resonance imaging across sites in the United States and Australia. Telix also says it has aligned with the U.S. Food and Drug Administration on a New Drug Application pathway that could support a distinct reimbursed indication if the study succeeds.
The potential change to the diagnostic pathway is substantial. PSMA-PET is already widely associated with staging and recurrent prostate cancer, but BiPASS is testing whether the imaging technology should move earlier, before a tissue diagnosis has even been made. Telix estimates that more than three million prostate biopsies are performed globally every year and cites literature indicating that as many as 75% can ultimately be negative, creating an obvious opportunity for a more accurate pre-biopsy filter.
Why are so many men sent for prostate biopsy even when cancer is not found?
Prostate-cancer diagnosis begins with probability rather than certainty. Elevated prostate-specific antigen, abnormal digital examination, family history and suspicious MRI findings can all increase concern, but none independently proves that clinically significant cancer is present. Biopsy therefore remains necessary when physicians need tissue to establish a diagnosis and determine tumor characteristics.
The problem is that biopsy can be uncomfortable, stressful and associated with bleeding, infection and other complications, while a negative procedure provides no therapeutic benefit. Telix also cites evidence suggesting roughly one in four patients may decline a physician recommendation for biopsy, meaning the current diagnostic pathway can lose patients even before the presence or absence of cancer is established.
What is BiPASS testing that MRI does not already provide?
Multiparametric MRI has already transformed prostate diagnosis by identifying suspicious lesions and helping physicians target biopsies more precisely. MRI is nevertheless not perfect, particularly when results are equivocal or when clinically significant tumors do not have highly distinctive anatomical characteristics.
PSMA-PET contributes functional information. Prostate-specific membrane antigen is frequently expressed at higher levels in prostate-cancer cells, and a radiolabeled PSMA tracer can reveal areas of increased biological uptake on PET imaging. BiPASS is therefore evaluating whether combining MRI anatomy with PSMA-PET biology can more accurately distinguish clinically significant cancer from findings unlikely to justify biopsy.
What did the earlier PRIMARY studies show?
BiPASS builds on the PRIMARY and PRIMARY2 studies, which examined the combination of PSMA-PET and MRI earlier in the diagnostic pathway. Telix says those studies found that adding PSMA-PET could significantly improve detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50%. The pivotal study is designed to determine whether that approach can be validated prospectively within a registrational framework acceptable to regulators.
That progression from promising academic evidence to a 350-patient Phase 3 trial is important. Diagnostic technologies often generate impressive retrospective or single-center data but struggle when tested prospectively across broader populations. BiPASS must show that the additional PET scan contributes enough independent value to justify greater imaging complexity and cost.
Why does FDA alignment on an NDA pathway matter?
Telix’s existing PSMA-PET products are already commercial imaging agents, but a new pre-biopsy use represents a different clinical indication. The company says its discussions with the FDA produced alignment around an NDA pathway that could establish a new product reimbursement route if BiPASS succeeds.
Reimbursement could be decisive because an imaging strategy may improve diagnostic accuracy yet still struggle to gain adoption if hospitals or insurers cannot justify paying for PET before biopsy. Telix’s commercial argument will therefore need to extend beyond sensitivity and specificity to whether the added scan avoids enough biopsies, complications and downstream costs to make the broader pathway economically attractive.
Could PSMA-PET eventually become routine before prostate biopsy?
BiPASS is attempting to answer exactly that question, but routine use is not yet established. Successful implementation would require convincing evidence that MRI plus PSMA-PET identifies clinically significant cancers accurately while safely allowing some men to avoid invasive tissue sampling. Physicians would also need clear thresholds determining when imaging is sufficiently reassuring and when biopsy remains necessary.
The potential market expansion for Telix is considerable because pre-biopsy evaluation includes a much larger population than patients already known to have prostate cancer and undergoing staging or recurrence imaging. That commercial upside raises the evidentiary bar rather than lowering it. Before PSMA-PET can move from cancer management into cancer diagnosis, BiPASS must show that adding another sophisticated imaging modality simplifies the patient journey rather than merely making it more expensive.
